Next Article in Journal
Stability Study of Isoniazid and Rifampicin Oral Solutions Using Hydroxypropyl-Β-Cyclodextrin to Treat Tuberculosis in Paediatrics
Next Article in Special Issue
Erythrocytes as Carriers: From Drug Delivery to Biosensors
Previous Article in Journal
Breaking Barriers: Bioinspired Strategies for Targeted Neuronal Delivery to the Central Nervous System
Review

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

1
Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650 Edegem, Belgium
2
Ariez International BV, 9000 Ghent, Belgium
3
Department of Hematology, University of Liège, 4000 Liège, Belgium
4
Department of Hematology, University Hospital Ghent, 9000 Ghent, Belgium
5
Faculty of Medicine and Dentistry, Université Catholique de Louvain, 1200 Woluwe-Saint-Lambert, Belgium
6
Department of Hematology, Institut Jules Bordet, 1000 Brussels, Belgium
7
Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium
8
Center for Cell Therapy & Regenerative Medicine (CCRG) and Division of Hematology, Antwerp University Hospital, 2650 Edegem, Belgium
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(2), 194; https://doi.org/10.3390/pharmaceutics12020194
Received: 14 December 2019 / Revised: 16 February 2020 / Accepted: 19 February 2020 / Published: 24 February 2020
(This article belongs to the Special Issue Cell-Based Drug-Delivery Platforms)
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively. View Full-Text
Keywords: CAR-T cells; immunotherapy; B-cell malignancies; CD19; BCMA CAR-T cells; immunotherapy; B-cell malignancies; CD19; BCMA
Show Figures

Figure 1

MDPI and ACS Style

Roex, G.; Feys, T.; Beguin, Y.; Kerre, T.; Poiré, X.; Lewalle, P.; Vandenberghe, P.; Bron, D.; Anguille, S. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics 2020, 12, 194. https://doi.org/10.3390/pharmaceutics12020194

AMA Style

Roex G, Feys T, Beguin Y, Kerre T, Poiré X, Lewalle P, Vandenberghe P, Bron D, Anguille S. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics. 2020; 12(2):194. https://doi.org/10.3390/pharmaceutics12020194

Chicago/Turabian Style

Roex, Gils, Tom Feys, Yves Beguin, Tessa Kerre, Xavier Poiré, Philippe Lewalle, Peter Vandenberghe, Dominique Bron, and Sébastien Anguille. 2020. "Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data" Pharmaceutics 12, no. 2: 194. https://doi.org/10.3390/pharmaceutics12020194

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop